Heidi Cuthbert - Author on Grafa
All
bioAffinity revenue hits $6.2M as CyPath lung adoption surges 87%
bioAffinity Technologies (NASDAQ:BIAF) reported fiscal year 2025 results that underscore an aggressive transition from a broad laboratory service model to a specialized, high-growth diagnostic powerhouse focused on early-stage lung cancer detection.










